Cargando…

Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect

BACKGROUND: Empirical antibiotic has been considered in severe COVID-19 although little data are available regarding concomitant infections. This study aims to assess the frequency of infections, community and hospital-acquired infections, and risk factors for infections and mortality during severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Saade, Anastasia, Moratelli, Giulia, Dumas, Guillaume, Mabrouki, Asma, Tudesq, Jean-Jacques, Zafrani, Lara, Azoulay, Elie, Darmon, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148396/
https://www.ncbi.nlm.nih.gov/pubmed/34036411
http://dx.doi.org/10.1186/s13613-021-00873-x
_version_ 1783697828881629184
author Saade, Anastasia
Moratelli, Giulia
Dumas, Guillaume
Mabrouki, Asma
Tudesq, Jean-Jacques
Zafrani, Lara
Azoulay, Elie
Darmon, Michael
author_facet Saade, Anastasia
Moratelli, Giulia
Dumas, Guillaume
Mabrouki, Asma
Tudesq, Jean-Jacques
Zafrani, Lara
Azoulay, Elie
Darmon, Michael
author_sort Saade, Anastasia
collection PubMed
description BACKGROUND: Empirical antibiotic has been considered in severe COVID-19 although little data are available regarding concomitant infections. This study aims to assess the frequency of infections, community and hospital-acquired infections, and risk factors for infections and mortality during severe COVID-19. METHODS: Retrospective single-center study including consecutive patients admitted to the intensive care unit (ICU) for severe COVID-19. Competing-risk analyses were used to assess cumulative risk of infections. Time-dependent Cox and fine and gray models were used to assess risk factors for infections and mortality. Propensity score matching was performed to estimate the effect of dexamethasone. RESULTS: We included 100 patients including 34 patients with underlying malignancies or organ transplantation. First infectious event was bacterial for 35 patients, and fungal for one. Cumulative incidence of infectious events was 27% [18–35] at 10 ICU-days. Prevalence of community-acquired infections was 7% [2.8–13.9]. Incidence density of hospital-acquired infections was 125 [91–200] events per 1000 ICU-days. Risk factors independently associated with hospital-acquired infections included MV. Patient’s severity and underlying malignancy were associated with mortality. Dexamethasone was associated with increased infections (36% [20–53] vs. 12% [4–20] cumulative incidence at day-10; p = 0.01). After matching, dexamethasone was associated with hospital-acquired infections (35% [18–52] vs. 13% [1–25] at 10 days, respectively, p = 0.03), except in the subset of patients requiring MV, and had no influence on mortality. CONCLUSIONS: In this population of COVID-19 patients with high prevalence of underlying immune defect, a high risk of infections was noted. MV and use of steroids were independently associated with infection rate. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00873-x.
format Online
Article
Text
id pubmed-8148396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-81483962021-05-26 Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect Saade, Anastasia Moratelli, Giulia Dumas, Guillaume Mabrouki, Asma Tudesq, Jean-Jacques Zafrani, Lara Azoulay, Elie Darmon, Michael Ann Intensive Care Research BACKGROUND: Empirical antibiotic has been considered in severe COVID-19 although little data are available regarding concomitant infections. This study aims to assess the frequency of infections, community and hospital-acquired infections, and risk factors for infections and mortality during severe COVID-19. METHODS: Retrospective single-center study including consecutive patients admitted to the intensive care unit (ICU) for severe COVID-19. Competing-risk analyses were used to assess cumulative risk of infections. Time-dependent Cox and fine and gray models were used to assess risk factors for infections and mortality. Propensity score matching was performed to estimate the effect of dexamethasone. RESULTS: We included 100 patients including 34 patients with underlying malignancies or organ transplantation. First infectious event was bacterial for 35 patients, and fungal for one. Cumulative incidence of infectious events was 27% [18–35] at 10 ICU-days. Prevalence of community-acquired infections was 7% [2.8–13.9]. Incidence density of hospital-acquired infections was 125 [91–200] events per 1000 ICU-days. Risk factors independently associated with hospital-acquired infections included MV. Patient’s severity and underlying malignancy were associated with mortality. Dexamethasone was associated with increased infections (36% [20–53] vs. 12% [4–20] cumulative incidence at day-10; p = 0.01). After matching, dexamethasone was associated with hospital-acquired infections (35% [18–52] vs. 13% [1–25] at 10 days, respectively, p = 0.03), except in the subset of patients requiring MV, and had no influence on mortality. CONCLUSIONS: In this population of COVID-19 patients with high prevalence of underlying immune defect, a high risk of infections was noted. MV and use of steroids were independently associated with infection rate. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00873-x. Springer International Publishing 2021-05-25 /pmc/articles/PMC8148396/ /pubmed/34036411 http://dx.doi.org/10.1186/s13613-021-00873-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Saade, Anastasia
Moratelli, Giulia
Dumas, Guillaume
Mabrouki, Asma
Tudesq, Jean-Jacques
Zafrani, Lara
Azoulay, Elie
Darmon, Michael
Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect
title Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect
title_full Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect
title_fullStr Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect
title_full_unstemmed Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect
title_short Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect
title_sort infectious events in patients with severe covid-19: results of a cohort of patients with high prevalence of underlying immune defect
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148396/
https://www.ncbi.nlm.nih.gov/pubmed/34036411
http://dx.doi.org/10.1186/s13613-021-00873-x
work_keys_str_mv AT saadeanastasia infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT moratelligiulia infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT dumasguillaume infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT mabroukiasma infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT tudesqjeanjacques infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT zafranilara infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT azoulayelie infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect
AT darmonmichael infectiouseventsinpatientswithseverecovid19resultsofacohortofpatientswithhighprevalenceofunderlyingimmunedefect